Pirenzepine ophthalmic - Novartis

Drug Profile

Pirenzepine ophthalmic - Novartis

Alternative Names: PIR 335; Pirenzepine ophthalmic gel

Latest Information Update: 05 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valley Forge Pharmaceuticals
  • Developer Novartis Ophthalmics
  • Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Myopia

Most Recent Events

  • 05 May 2008 Discontinued - Phase-II for Myopia in Hong Kong (Ophthalmic)
  • 05 May 2008 Discontinued - Phase-II for Myopia in Singapore (Ophthalmic)
  • 05 May 2008 Discontinued - Phase-II for Myopia in Thailand (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top